{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:31Z","timestamp":1789794151205,"version":"4.0.1"},"reference-count":53,"publisher":"Japan Atherosclerosis Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5551\/jat.66330","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:12:14Z","timestamp":1789337534000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) in Japan: An Expert Consensus Statement"],"prefix":"10.5551","author":[{"given":"Masayuki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Life Sciences and Bioethics, Institute of Science Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Technology, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Insured Medical Care Management, Institute of Science Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Funabashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyorin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Michikura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"},{"name":"Department of General Internal Medicine, The Jikei University School of Medicine"},{"name":"Section of Internal Medicine of Metabolism and Nutrition, The Jikei University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokg\u00f6zoglu L, Tybj\u00e6rg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31: 2844-2853","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol, 2014; 63: 470-477","DOI":"10.1016\/j.jacc.2013.09.038"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybj\u00e6rg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition\u2013 Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol, 2018; 3: 619-627","DOI":"10.1001\/jamacardio.2018.1470"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J, 2019; 40: 2760-2770","DOI":"10.1093\/eurheartj\/ehy902"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol, 2022; 80: 934-946","DOI":"10.1016\/j.jacc.2022.06.019"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2022; 42: e48-e60","DOI":"10.1161\/ATV.0000000000000147"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Par\u00e9 G, \u00c7aku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S; INTERHEART Investigators. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 2019; 139: 1472-1482","DOI":"10.1161\/CIRCULATIONAHA.118.034311"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Reyes-Soffer G. Race\/ethnicity and lipoprotein(a). Curr Opin Lipidol, 2021; 32: 163-166","DOI":"10.1097\/MOL.0000000000000753"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Utermann G. The genetic architecture and evolution of lipoprotein(a). Curr Opin Lipidol, 1999; 10: 133-141","DOI":"10.1097\/00041433-199904000-00007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J, 2012; 33: 325-334","DOI":"10.1093\/eurheartj\/ehr350"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yamada T, Tada H, Ogura M, Funabashi S, Yoshida H, Hiraishi C, Ebihara T, Hadano T, Masaki T, Takeji Y, Fukatsu K, Egawa M, Kataoka Y, Michikura M, Shishikura D, Fujioka S, Sasano T, Maehara T, Ai M, Shiba-Harada M, Yoshida M. Lipoprotein(a) Distribution and Cardiovascular Risk in Japan: Insights from a Multi-center LEAP Study. J Atheroscler Thromb, 2026; 33: 1049-1059","DOI":"10.5551\/jat.66185"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fujii E, Ako J, Takahashi Y, Toda M, Iekushi K, Yamashita S. Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan. J Atheroscler Thromb, 2025; 32: 421-438","DOI":"10.5551\/jat.64953"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, 2016; 388: 2239-2253","DOI":"10.1016\/S0140-6736(16)31009-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) O\u2019Donoghue ML, G L\u00f3pez JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J, 2022; 251: 61-69","DOI":"10.1016\/j.ahj.2022.05.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH; ALPACA Trial Investigators. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med, 2025; 392: 1673-1683","DOI":"10.1056\/NEJMoa2415818"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J, 2025; 287: 1-9","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA, 2023; 330: 1042-1053","DOI":"10.1001\/jama.2023.16503"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li JJ, Ma CS, Zhao D, Yan XW, Ye P, Chen H, Li Y, Yuan Z, Zhang R, Zhao S, Lu G, Liang C, Dong Y, Chen Z, Peng D, Tang Y, Wang F, Zhou Z, Sun Y, Liu J, Guo Y, Yuan H, Wu N, Zhu Y; Beijing Heart Society and Expert Committee. Lipoprotein(a) in Chinese populations. JACC Asia, 2022; 2: 653-665","DOI":"10.1016\/j.jacasi.2022.08.015"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kronenberg F, Bedlington N, Ademi Z, Geant\u0103 M, Silberzahn T, Rijken M, Kaal A, Harada-Shiba M, Chen Z, Thanassoulis G, Eliasen B, Eisel\u00e9 JL, Wiegman A, Ballantyne CM, Broome E, Calabr\u00f2 M, Corral P, Dol A, Donato LJ, Evans E, Funabashi S, Gouni-Berthold I, Gutierrez Ibarluzea I, Johnson N, Lane J, Mora S, Nordestgaard BG, Pe\u0107in I, Kaal-Poppelaars R, Langlois MR, Ray KK, Rodenbach A, Santos RD, Stroes ESG, Tada H, Vrabl\u00edk M, Winokur M, Yoshida M, Nicholls SJ, Daccord M. The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis, 2025; 406: 119218","DOI":"10.1016\/j.atherosclerosis.2025.119218"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Morton JI, Kronenberg F, Daccord M, Bedlington N, Geanta M, Silberzahn T, Chen Z, Eisele JL, Eliasen B, Harada-Shiba M, Rijken M, Wiegman A, Thanassoulis G, Kamstrup PR, Gutierrez-Ibarluzea I, Coral P, Santos RD, Stroes E, Vrablik M, Watts GF, Ballantyne CM, Mora S, Nordestgaard BG, Ray KK, Nicholls SJ, Ademi Z; on behalf of the Lp(a) International Taskforce (ITF) initiative. Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis. Atherosclerosis, 2025; 409: 120447","DOI":"10.1016\/j.atherosclerosis.2025.120447"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Miida T, Hirayama S, Fukushima Y, Hori A, Ito S, Hinata M, Wakita M, Tabata H, Tamura Y, Watada H, Kawamori R, Vesper HW, Cobbaert CM. Harmonization of Lp(a) immunoassays in Japan. J Atheroscler Thromb, 2025; 32: 580-595","DOI":"10.5551\/jat.65238"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tada H, Takamura M, Kawashiri MA. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb, 2019; 26: 583-591","DOI":"10.5551\/jat.RV17034"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, M\u00e4\u00e4tt\u00e4 A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Yl\u00e4-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic. Nature, 2018; 558: 301-306","DOI":"10.1038\/s41586-018-0198-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tsimikas S, Szarek M, Cobbaert CM, Romijn F, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Yuan C, Gong XM, Goodman SG, White HD, Witztum JL, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators. Oxidized phospholipids, lipoprotein(a), and cardiovascular outcomes after ACS. Circulation, 2025; 152: 1666-1678","DOI":"10.1161\/CIRCULATIONAHA.125.073855"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bhatia HS, Dweck MR, Craig N, Capoulade R, Pibarot P, Trainor PJ, Whelton SP, Rikhi R, Lidani KCF, Post WS, Tsai MY, Criqui MH, Shapiro MD, Budoff MJ, DeFilippis AP, Thanassoulis G, Tsimikas S. Oxidized phospholipids and calcific aortic valve disease. J Am Coll Cardiol, 2024; 84: 2430-2441","DOI":"10.1016\/j.jacc.2024.08.070"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Januzzi JL Jr, van Kimmenade RRJ, Liu Y, Hu X, Browne A, Plutzky J, Tsimikas S, Blankstein R, Natarajan P. Oxidized phospholipids, lipoprotein(a), and heart failure. J Am Heart Assoc, 2024; 13: e034774","DOI":"10.1161\/JAHA.124.034774"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Coassin S, Kronenberg F. Complexity of genetic variation in the LPA gene. Atherosclerosis, 2022; 349: 17-35","DOI":"10.1016\/j.atherosclerosis.2022.04.003"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pfeferman MB, Rashedi S, Lip GYH, Weber C, O\u2019Donoghue ML, Nissen S, Nicholls SJ, Natarajan P, Plutzky J, Libby P, Goldhaber SZ, Piazza G, Bikdeli B. Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications. Thromb Haemost, 2025; 125: 1069-1084","DOI":"10.1055\/a-2674-5114"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y, Igarashi M. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol, 1995; 141: 815-821","DOI":"10.1093\/oxfordjournals.aje.a117516"},{"key":"31","unstructured":"31) Ohtsuki T. Serum lipoprotein(a) levels in healthy Japanese subjects. Hiroshima J Med Sci, 1993; 42: 73-81"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Arafa A, Kato Y, Kokubo Y, Khairan P, Matsumoto C, Nakao YM, Kataoka Y, Harada-Shiba M. Lipoprotein(a) distribution in the Suita Study. J Atheroscler Thromb, 2025; 32: 1139-1149","DOI":"10.5551\/jat.65437"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sawabe M, Tanaka N, Mieno MN, Ishikawa S, Kayaba K, Nakahara K, Matsushita S; JMS Cohort Study Group. Lipoprotein(a) distribution in the JMS cohort. PLoS One, 2012; 7: e31954","DOI":"10.1371\/journal.pone.0031954"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Yoshida H, Kroes M, Sakai Y, Takahashi Y, Yamanaka Y, Crawford B, Ako J. Lipoprotein(a) in Japanese patients with cardiovascular disease: A Systematic Review. JACC Asia, 2025; 5: 1525-1539","DOI":"10.1016\/j.jacasi.2025.08.017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Lipoprotein(a) in familial hypercholesterolemia. Circ J, 2016; 80: 512-518","DOI":"10.1253\/circj.CJ-15-0999"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yamamoto Y. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb, 2023; 30: 531-557","DOI":"10.5551\/jat.CR006"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Shishikura D, Harada-Shiba M, Michikura M, Fujioka S, Fujisaka T, Morita H, Kanzaki Y, Hoshiga M. Additive ASCVD risk of lipoprotein(a) in FH. J Atheroscler Thromb, 2025; 32: 100-110","DOI":"10.5551\/jat.65009"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Tada H, Yamagami K, Nishikawa T, Yoshida T, Teramoto R, Sakata K, Takamura M, Kawashiri MA. Lipoprotein(a) and chronic kidney disease. Intern Med, 2020; 59: 1705-1710","DOI":"10.2169\/internalmedicine.4503-20"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Tada H, Kojima N, Yamagami K, Takeji Y, Sakata K, Usui S, Kawashiri MA, Takamura M. Lipoprotein(a) and family history of CAD. J Lipid Atheroscler, 2025; 14: 120-127","DOI":"10.12997\/jla.2025.14.1.120"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Marcovina SM, Albers JJ. Lipoprotein(a) measurements for clinical application. J Lipid Res, 2016; 57: 526-537","DOI":"10.1194\/jlr.R061648"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Dikaios I, Althaus H, Angles-Cano E, Ceglarek U, Coassin S, Cobbaert CM, Delatour V, Dieplinger B, Grimmler M, Hoofnagle AN, Kostner GM, Kronenberg F, Kuklenyik Z, Lyle AN, Prinzing U, Ruhaak LR, Scharnagl H, Vesper HW, Deprez L; on behalf of the IFCC Working Group on Apolipoproteins by Mass Spectrometry (WG-APO MS). Commutability Assessment of Candidate Reference Materials for Lipoprotein(a). Clin Chem, 2023; 69: 262-272","DOI":"10.1093\/clinchem\/hvac203"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ruhaak LR, Romijn FPHTM, Begcevic Brkovic I, Kuklenyik Z, Dittrich J, Ceglarek U, Hoofnagle AN, Althaus H, Angles-Cano E, Coassin S, Delatour V, Deprez L, Dikaios I, Kostner GM, Kronenberg F, Lyle A, Prinzing U, Vesper HW, Cobbaert CM; on behalf of the IFCC Working Group for Standardization of Apolipoproteins by Mass Spectrometry. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests. Clin Chem, 2023; 69: 251-261","DOI":"10.1093\/clinchem\/hvac204"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of molar versus mass lipoprotein(a). J Clin Lipidol, 2018; 12: 1313-1323","DOI":"10.1016\/j.jacl.2018.07.003"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol, 2013; 62: 1575-1579","DOI":"10.1016\/j.jacc.2013.06.051"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol, 2014; 63: 520-527","DOI":"10.1016\/j.jacc.2013.09.042"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol, 2020; 40: 255-266","DOI":"10.1161\/ATVBAHA.119.312951"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, 2018; 392: 1311-1320","DOI":"10.1016\/S0140-6736(18)31652-0"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Kindborg G, Eriksson Hogling D, H\u00e4bel H, Yan J, Hallerb\u00e4ck T, Lindhe \u00d6, Hagstr\u00f6m E, Andersson DP, Littmann K, Brinck J. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Eur Heart J, 2026; 47: 3390-3400","DOI":"10.1093\/eurheartj\/ehaf677"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D; Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels. Nat Clin Pract Cardiovasc Med, 2009; 6: 229-239","DOI":"10.1038\/ncpcardio1456"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Boden WE, Sidhu MS, Toth PP. Therapeutic role of niacin. J Cardiovasc Pharmacol Ther, 2014; 19: 141-158","DOI":"10.1177\/1074248413514481"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Perrot N, Verbeek R, Sandhu M, Boekholdt SM, Hovingh GK, Wareham NJ, Khaw KT, Arsenault BJ. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a). Atherosclerosis, 2017; 256: 47-52","DOI":"10.1016\/j.atherosclerosis.2016.11.010"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66330\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:32:53Z","timestamp":1789792373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66330\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":53,"URL":"https:\/\/doi.org\/10.5551\/jat.66330","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"66330"}}